Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 4/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5499368 | 0.90 | PTPN1 (0.39) | NLRP3PTPN1KCNH2DHFRAPP | |
| SCHEMBL4517519 | 0.89 | PTPN1 (0.51) | NLRP3PTPN1KCNH2DHFRHRH4 | |
| SCHEMBL4531641 | 0.81 | DHFR (0.46) | NLRP3PTPN1KCNH2DHFRHRH4 | |
| SCHEMBL4533460 | 0.81 | HRH4 (0.55) | NLRP3PTPN1DHFRHRH4APP | |
| SCHEMBL4526439 | 0.80 | DHFR (0.50) | NLRP3PTPN1DHFR | |
| SCHEMBL4527908 | 0.79 | PTPN1 (0.50) | PTPN1DHFRAPP | |
| SCHEMBL4523940 | 0.79 | PTPN1 (0.64) | NLRP3PTPN1HRH4 | |
| SCHEMBL4528291 | 0.79 | DHFR (0.46) | NLRP3KCNH2DHFRAPP | |
| Trifluoroacetic Acid SCHEMBL4528727 | 0.79 | KCNH2 (0.38) | NLRP3PTPN1KCNH2HRH4 | |
| SCHEMBL4526172 | 0.78 | PTPN1 (0.59) | NLRP3PTPN1DHFRHRH4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | claimed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | claimed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | NLRP3 618/4885PTPN1 2/4885KCNH2 3854/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | NLRP3 618/4885PTPN1 2/4885KCNH2 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.